Celsus Therapeutics PLC Announces Details of Annual General Meeting of Shareholders

NEW YORK and LONDON, May 14, 2014 (GLOBE NEWSWIRE) -- Celsus Therapeutics Plc (Nasdaq:CLTX), an emerging growth, development-stage biotech company, announced today that the annual general meeting of its shareholders will be held on Thursday, June 19, 2014 at 10:00 a.m. (Local Time, BST in UK), at 53 Davies Street, Mayfair, London W1K 5JH, United Kingdom.

The Company's annual report on Form 20-F for the fiscal year ended December 31, 2013, containing its annual consolidated financial statements for the year ended December 31, 2013 and the auditors' report thereon, was filed with the Securities and Exchange Commission on March 24, 2014. The Company distributed the notice of annual general meeting, proxy statement and form of proxy on May 12, 2014.

The annual report, notice of the annual general meeting and proxy statement, form of proxy and ADR voting card are available on the corporate governance page of the Company's corporate website, www.celsustx.com. Shareholders may also obtain a copy of the annual report, notice of the annual general meeting and proxy statement, form of proxy and ADR voting card, free of charge, by sending a written request to the Company at 1500 Broadway, 12th Floor, New York, NY 10036 (attention: Investor Relations, telephone: 1-646-350-0702) or ir@celsustx.com.

About Celsus Therapeutics Plc (Company No. 05252842)

Celsus Therapeutics is an emerging clinical stage company focused on the development of a new class of non-steroidal, synthetic anti-inflammatory drugs termed Multi-Functional Anti-Inflammatory Drugs or MFAIDs. Celsus's MFAIDs represent a new therapeutic platform for the treatment of a broad array of inflammatory diseases, such as allergies and autoimmune diseases. Presently, the Company's lead drug candidate in its clinical pipeline is MRX-6, an MFAID topical cream treatment under development for treating skin inflammatory disorders, specifically allergic contact dermatitis and atopic dermatitis, also known as eczema. Other potential treatments in preclinical development include OPX-1 for ocular inflammation, CFX-1 for cystic fibrosis, and MRX-5 for inflammatory bowel disease.


This press release contains "forward-looking statements" that involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms including "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would," "hope," "look forward" and similar expressions intended to identify forward-looking statements. Forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 20-F discusses some of the important risk factors that may affect our business, results of operations and financial condition. Unless we are required to do so under applicable laws, we do not intend to update or revise any forward-looking statements.

CONTACT: Investor Relations Contact The Trout Group Tricia Truehart ttruehart@troutgroup.com 646-378-2953Source:Celsus Therapeutics